Table 3.

Selected retrospective studies examining the association between perioperative administration of NSAID and cancer recurrence and overall survival rates.

Author	Year	NSAID	Number of patients	Cancer type	Findings
Forget et al. (118)	2011	Ketorolac	1,111	Prostate cancer	Intraoperative use of Ketorolac did not significantly improve the incidence of biochemical recurrence-free survival rates
Forget et al. (119)	2014	Ketorolac and Diclofenac	720	Breast cancer	Intraoperative use of ketorolac or diclofenac was associated with improved outcomes in cancer recurrence and overall survival rates.
Yeh et al. (120)	2015	Non-specific	15,574	Hepatocellular carcinoma	The use of NSAIDS was associated with a reduced risk of early HCC recurrence within 2 years after liver surgery.
Lee et al. (121)	2016	Ketorolac, ibuprofen, rofecoxib or celecoxib.	1,637	Non-small-cell lung cancer	Perioperative use of NSAID did not significantly improve cancer recurrence and overall survival rates.
Huang et al. (122)	2018	Flurbiprofen and dexamethasone combination	588	Non-small-cell lung cancer	Perioperative combined administration of dexamethasone and flubiprofen was associated with longer survival rates.